المؤلفون: Bolland, Meilyn, Malaise, Olivier, Ribbens, Clio

المصدر: Revue Médicale de Liège, 78 (4), 239 - 244 (2023-04)

مصطلحات موضوعية: Anti-sclerostin antibody, Fracture, Osteoporosis, Romosozumab, romosozumab, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Bone Density Conservation Agents, Humans, Female, Bone Density, Antibodies, Monoclonal/pharmacology, Antibodies, Monoclonal/therapeutic use, Antibodies, Monoclonal, Humanized/pharmacology, Antibodies, Monoclonal, Humanized/therapeutic use, Osteoporosis, Postmenopausal/drug therapy, Bone Resorption, Bone Density Conservation Agents/pharmacology, Bone Density Conservation Agents/therapeutic use, Osteoporosis, Postmenopausal, Medicine (all), Human health sciences, Rheumatology, Sciences de la santé humaine, Rhumatologie

العلاقة: urn:issn:0370-629X; urn:issn:2566-1566

الوصول الحر: https://orbi.uliege.be/handle/2268/312146Test

المؤلفون: M R McClung, A L Clark

المصدر: Climacteric. 25:60-66

مصطلحات موضوعية: medicine.medical_specialty, Abaloparatide, Osteoporosis, Romosozumab, Fractures, Bone, Bone Density, Teriparatide, osteoanabolic, medicine, Humans, abaloparatide, Intensive care medicine, Osteoporosis, Postmenopausal, romosozumab, Postmenopausal women, Bone Density Conservation Agents, Diphosphonates, business.industry, Obstetrics and Gynecology, General Medicine, sequence, medicine.disease, Menopause, Female, business, Very high risk, medicine.drug, Bone mass

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::406e842e15797b728fdd9070ef88de0aTest
https://doi.org/10.1080/13697137.2021.1953463Test

المؤلفون: Bolland, Meilyn, Malaise, Olivier, Ribbens, Clio

المصدر: Revue Médicale de Liège, 78 (4), 239 - 244 (2023-04)

مصطلحات موضوعية: Anti-sclerostin antibody, Fracture, Osteoporosis, Romosozumab, Antibodies, Monoclonal, Humanized, Bone Density Conservation Agents, Humans, Female, Bone Density, Monoclonal/pharmacology, Monoclonal/therapeutic use, Humanized/pharmacology, Humanized/therapeutic use, Postmenopausal/drug therapy, Bone Resorption, Bone Density Conservation Agents/pharmacology, Bone Density Conservation Agents/therapeutic use, Postmenopausal, Medicine (all), Human health sciences, Rheumatology, Sciences de la santé humaine, Rhumatologie

العلاقة: urn:issn:0370-629X; urn:issn:2566-1566; https://orbi.uliege.be/handle/2268/312146Test; info:hdl:2268/312146; scopus-id:2-s2.0-85152620812; info:pmid:37067842

الإتاحة: https://orbi.uliege.be/handle/2268/312146Test

المؤلفون: J C Forfar, Lorenz C. Hofbauer, Bente L. Langdahl

المصدر: Langdahl, B L, Hofbauer, L C & Forfar, J C 2021, ' Cardiovascular Safety and Sclerostin Inhibition ', The Journal of clinical endocrinology and metabolism, vol. 106, no. 7, pp. 1845-1853 . https://doi.org/10.1210/clinem/dgab193Test

مصطلحات موضوعية: 0301 basic medicine, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, Osteoporosis, sclerostin, Cardiovascular System, Biochemistry, chemistry.chemical_compound, 0302 clinical medicine, Endocrinology, Bone Density, Osteogenesis, Osteoporosis, Postmenopausal, Bone Density Conservation Agents, biology, Antibodies, Monoclonal, Middle Aged, medicine.anatomical_structure, Cardiovascular Diseases, RANKL, Female, Risk, medicine.medical_specialty, Romosozumab, 030209 endocrinology & metabolism, 03 medical and health sciences, cardiovascular safety, Osteoclast, Internal medicine, Product Surveillance, Postmarketing, medicine, Humans, Adverse effect, Adaptor Proteins, Signal Transducing, Proportional Hazards Models, romosozumab, business.industry, Biochemistry (medical), medicine.disease, osteoporosis, Clinical trial, 030104 developmental biology, Clinical Trials, Phase III as Topic, chemistry, Heart Disease Risk Factors, Relative risk, biology.protein, Sclerostin, business, Osteoporotic Fractures

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::735a36ada85530b408b68cbf207c2a06Test
https://doi.org/10.1210/clinem/dgab193Test

المؤلفون: Stéphane Horlait, Donald Betah, Jacques P. Brown, Cesar Libanati, Yifei Shi, Rogely W. Boyce, Erik Fink Eriksen, Pascale Chavassieux, Roland Chapurlat

المصدر: Journal of Bone and Mineral Research. 37:36-40

مصطلحات موضوعية: medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Osteoporosis, Romosozumab, Urology, Placebo, chemistry.chemical_compound, Bone Density, Osteogenesis, medicine, Humans, Orthopedics and Sports Medicine, Osteoporosis, Postmenopausal, Bone Density Conservation Agents, business.industry, Antibodies, Monoclonal, Middle Aged, medicine.disease, Resorption, Clinical trial, Denosumab, chemistry, Concomitant, Sclerostin, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbe42f8075c8218191df7e01ef61cc7eTest
https://doi.org/10.1002/jbmr.4457Test

المؤلفون: Bin Lu, Yan Li, Haobo Jia, Shan Zhu, Tian Aixian, Jianxiong Ma, Xinlong Ma

المصدر: Orthopaedic Surgery
Orthopaedic Surgery, Vol 13, Iss 7, Pp 1941-1950 (2021)

مصطلحات موضوعية: medicine.medical_specialty, Romosozumab, Review Article, Cochrane Library, law.invention, Postmenopausal osteoporosis, Randomized controlled trial, law, Bone Density, Internal medicine, Teriparatide, medicine, Humans, Orthopedics and Sports Medicine, Adverse effect, Review Articles, Osteoporosis, Postmenopausal, Femoral neck, Randomized Controlled Trials as Topic, Orthopedic surgery, Bone Density Conservation Agents, business.industry, Incidence (epidemiology), Antibodies, Monoclonal, medicine.anatomical_structure, Meta-analysis, Randomized controlled trials, Systematic review, Surgery, business, RD701-811, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::136403ac4b2e2ab618281ebd08c62e79Test
http://europepmc.org/articles/PMC8528978Test

المؤلفون: Willem F. Lems, Hennie G. Raterman, Laura P. B. Elbers

المصدر: Drugs
Elbers, L P B, Raterman, H G & Lems, W F 2021, ' Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review ', Drugs, vol. 81, no. 14, pp. 1645-1655 . https://doi.org/10.1007/s40265-021-01587-xTest

مصطلحات موضوعية: medicine.medical_specialty, Bone Density Conservation Agents, business.industry, Osteoporosis, Romosozumab, Review Article, medicine.disease, Bone remodeling, Discontinuation, Denosumab, Zoledronic acid, medicine.anatomical_structure, Bone Density, Internal medicine, medicine, Teriparatide, Humans, Pharmacology (medical), Bone Remodeling, business, Osteoporotic Fractures, Randomized Controlled Trials as Topic, medicine.drug, Femoral neck

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12a84808e5828eb1c382c5249746ced5Test
https://doi.org/10.1007/s40265-021-01587-xTest

المؤلفون: S Palacios

المصدر: Climacteric. 25:43-49

مصطلحات موضوعية: medicine.medical_specialty, Abaloparatide, Osteoporosis, Romosozumab, Anabolic Agents, Bone Density, Weight loss, Teriparatide, Internal medicine, medicine, Vitamin D and neurology, Humans, Osteoporosis, Postmenopausal, Bone Density Conservation Agents, Diphosphonates, business.industry, Obstetrics and Gynecology, General Medicine, medicine.disease, Denosumab, Quality of Life, Female, medicine.symptom, business, Osteoporotic Fractures, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2ce69b2576bf2491c7dbb588bb0c000Test
https://doi.org/10.1080/13697137.2021.1951697Test

المؤلفون: Xavier Nogués, Roland Chapurlat, Fabio Massari, Christopher Recknor, Cristiano A. F. Zerbini, Roberto Civitelli, Tony M. Keaveny, Arkadi Chines, Zhenxun Wang, A. Joseph Foldes, Jacques P. Brown, Klaus Engelke, Tobias J. de Villiers, Cesar Libanati, Mary Oates

المصدر: Journal of Bone and Mineral Research. 36:2139-2152

مصطلحات موضوعية: musculoskeletal diseases, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Osteoporosis, Romosozumab, Urology, Bone strength, Bone Density, Humans, Medicine, Orthopedics and Sports Medicine, Quantitative computed tomography, Osteoporosis, Postmenopausal, Reduction (orthopedic surgery), Bone mineral, Lumbar Vertebrae, Postmenopausal women, Alendronate, Bone Density Conservation Agents, medicine.diagnostic_test, business.industry, Antibodies, Monoclonal, medicine.disease, Postmenopause, Female, Lumbar spine, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41f2f06709ae20272b07f6f89963d899Test
https://doi.org/10.1002/jbmr.4409Test

المؤلفون: Paul D Miller, Jonathan D Adachi, Ben‐Hur Albergaria, Angela M Cheung, Arkadi A Chines, Evelien Gielen, Bente L Langdahl, Akimitsu Miyauchi, Mary Oates, Ian R Reid, Norma Ruiz Santiago, Mark Vanderkelen, Zhenxun Wang, Zhigang Yu

المصدر: Miller, P D, Adachi, J D, Albergaria, B H, Cheung, A M, Chines, A A, Gielen, E, Langdahl, B L, Miyauchi, A, Oates, M, Reid, I R, Santiago, N R, Vanderkelen, M, Wang, Z & Yu, Z 2022, ' Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease ', Journal of Bone and Mineral Research, vol. 37, no. 8, pp. 1437-1445 . https://doi.org/10.1002/jbmr.4563Test

مصطلحات موضوعية: RENAL-FUNCTION, TERIPARATIDE, MENOPAUSE, PHARMACOLOGICAL MANAGEMENT, ANABOLICS, Endocrinology, Diabetes and Metabolism, OSTEOPOROSIS, ROMOSOZUMAB, Endocrinology & Metabolism, Fractures, Bone, Bone Density, Humans, Orthopedics and Sports Medicine, Renal Insufficiency, Chronic, ALENDRONATE, Osteoporosis, Postmenopausal, DENOSUMAB, Science & Technology, Alendronate, Bone Density Conservation Agents, Femur Neck, CHRONIC KIDNEY DISEASE, Antibodies, Monoclonal, FRACTURE, Postmenopause, Osteoporosis, Female, BONE-MINERAL DENSITY, Life Sciences & Biomedicine, INTERVENTION

وصف الملف: Print-Electronic

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::275b6557dc439138ab47615df0fb7c5cTest
https://pure.au.dk/portal/da/publications/efficacy-and-safety-ofTest-romosozumab-among-postmenopausal-women-with-osteoporosis-and-mildtomoderate-chronic-kidney-disease(6e1159b5-a9aa-415a-afe4-1b1285f1835b).html